Tigris Pharmaceuticals, Inc.
Our Mission Recent News



Tigris Pharmaceuticals is a development stage biopharmaceutical company devoted to finding breakthrough therapies for cancer patients.

With proven records of the management team in guiding molecules from early stage of clinical development to successful worldwide approvals, we offer large pharmaceutical drug development expertise in conjunction with the agility and speed of a small organization.



May 15, 2008 - Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute » Read

January 31, 2008 - Tigris Pharmaceuticals Appoints Pedro Granadillo to Board of Directors » Read

January 30, 2008 - Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors » Read



AACR Annual Meeting 2008
April 12-16, 2008
San Diego, CA

Oral Presentation of Aminoflavone
"Breast cancer cells resistant to anti-hormone treatments retain sensitivity to Aminoflavone (NSC 686288)"